Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Vitamins

Vitamins

Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced in our...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

S-nitrosylation contributes to ER stress and aggresome formation in secosterol-B-mediated endothelial dysfunction.

Journal of lipid research·2026

Same author

Nutrigenomics of fat-soluble vitamins and micronutrients in hepatocyte lipotoxicity and MASLD.

Progress in lipid research·2026

Same author

Identifying effective surveillance measures for swine pathogens using contact networks and mathematical modeling.

PloS one·2025

Same author

Multivariate Data Analysis Methods and Their Application in Lipidomics: A Gentle Comment on Appropriateness and Reliability Criteria.

Journal of pineal research·2025

Same author

Impact of Extra-Virgin Olive Oil Storage Conditions on Phenolic Content and Wound-Healing Properties.

Foods (Basel, Switzerland)·2025

Same author

Garcinoic acid enhances inflammation resolution against colitis by activating Nrf2 dependent efferocytosis.

Free radical biology & medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Do statins cause myopathy by lowering vitamin E levels?

Francesco Galli¹, Luigi Iuliano

¹Faculty of Pharmacy, Department of Internal Medicine, Section of Applied Biochemistry and Nutritional Sciences, University of Perugia, Via del Giochetto, 06126 Perugia, Italy. f.galli@unipg.it

Medical Hypotheses

|November 10, 2009

Summary

This summary is machine-generated.

Statins may increase the risk of myopathy by lowering vitamin E levels. This study hypothesizes that vitamin E deficiency, a known side effect of statins, could be a risk factor for developing statin-associated myopathy.

Related Experiment Videos

Last Updated: Jun 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Biochemistry
Molecular Biology
Pharmacology

Background:

Statins and lipid-lowering drugs are known to reduce blood levels of fat-soluble components.
Vitamin E (alpha-tocopherol) levels can be decreased by these medications.
The clinical implications of statin-induced vitamin E deficiency have not been well-established.

Purpose of the Study:

To propose a hypothesis linking vitamin E deficiency to statin-associated myopathy.
To explore the potential role of vitamin E deficiency as a risk factor for myopathy.
To suggest the need for further investigation into this potential adverse effect.

Main Methods:

Review of existing biochemical and molecular evidence.
Analysis of homeostatic and molecular responses to vitamin E deficiency in skeletal muscle cells.
Formulation of a hypothesis based on current scientific understanding.

Main Results:

Recent evidence suggests specific responses in skeletal muscle to vitamin E deficiency.
These responses may indicate a link between vitamin E status and muscle health.
The study presents a novel hypothesis regarding statin-induced myopathy.

Conclusions:

Vitamin E deficiency, induced by statins, is hypothesized as a risk factor for statin-associated myopathy.
Further research is required to validate this hypothesis.
Proactive measures such as diagnosing and preventing vitamin E deficiency may be warranted during statin therapy.